In the modern treatment of advanced HCC, the combination of the checkpoint inhibitor atezolizumab and the VEGF inhibitor bevacizumab, or, alternatively, combined checkpoint inhibition with tremelimumab and durvalumab are currently the first choice for patients with an ECOG (Eastern Cooperative Oncology Group Performance) 0–1 status who are classified as Child Pugh A25. Here, VEGFA is linked to hepatocellular carcinoma.